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Background:  The presence of left ventricular late gadolinium enhancement (LGE) in hypertrophic cardiomyopathy (HCM) patients is 
associated with an increased risk of heart failure and mortality. It remains unclear if myofilament mutation positive or negative HCM patients 
have different amounts of late gadolinium enhancement.
methods:  Patients with HCM underwent genetic analysis for myofilament mutations and contrast enhanced cardiac MRI at the time of 
initial presentation. LGE was quantified using a signal intensity algorithm (DiagnosoftTM VIRTUE software). The presence of fibrosis was 
defined as >1% LV myocardial volume with a signal intensity threshold of 4 standard deviations above the mean signal intensity of normal 
myocardium. Non-parametric tests were used for statistical analysis.
results:  Forty-six HCM patients were analyzed (29 myofilament mutation positive, 17 myofilament mutation negative). The mutation 
positive HCM group consisted of 16 MYBPC3, 10 MYH7, and 3 TNNI3 mutation carriers. Despite the mutation positive HCM carriers 
being significantly younger at presentation than mutation negative HCM subjects (32±17 vs 52±12 yrs, p<0.001), both groups had a 
similar prevalence of LGE (62% vs 55%, p=0.59). The total amount of LGE was similar between both mutation positive and negative HCM 
subjects (5.9±10 vs 5.7±8%, p=0.97). Likewise, the maximal wall thickness was similar between both mutation positive and negative 
subjects with LGE (24±7.3 vs 22±4.4mm, p=0.58) and without LGE (18±4.9 vs 19±3.6mm, p=0.39). Independent of genotype, LGE positive 
subjects had increased maximal wall thickness compared to LGE negative subjects (23±6.6 vs 18±4.5mm, p<0.03). There were no 
significant differences between different types of myofilament mutations and the prevalence or amount of LGE.
conclusion:  HCM patients with and without myofilament mutations develop similar levels of myocardial hypertrophy and LGE despite 
myofilament mutation carriers presenting at a much younger age. Further investigation is warranted to delineate the differential 
mechanisms influencing the myocardial remodeling process in myofilament mutation positive and negative HCM patients.
